TY - BOOK AU - Hoen, E. PY - 2016 DA - 2016// TI - Private Patents and Public Health: Changing Intellectual Property Rules for Access to Medicines PB - Health Action International CY - Amsterdam ID - Hoen2016 ER - TY - JOUR AU - Sell, S. K. PY - 2007 DA - 2007// TI - TRIPS-plus free trade agreements and access to medicines JO - Liverpool Law Rev VL - 28 UR - https://doi.org/10.1007/s10991-007-9011-8 DO - 10.1007/s10991-007-9011-8 ID - Sell2007 ER - TY - JOUR AU - Lopert, R. AU - Gleeson, D. PY - 2013 DA - 2013// TI - The high price of "free" trade: US trade agreements and access to medicines JO - J Law Med Ethics VL - 41 UR - https://doi.org/10.1111/jlme.12014 DO - 10.1111/jlme.12014 ID - Lopert2013 ER - TY - BOOK AU - Sell, S. K. PY - 2003 DA - 2003// TI - Private power, public law: the globalization of intellectual property rights PB - Cambridge University Press CY - Cambridge UR - https://doi.org/10.1017/CBO9780511491665 DO - 10.1017/CBO9780511491665 ID - Sell2003 ER - TY - BOOK AU - May, C. PY - 2000 DA - 2000// TI - A global political economy of intellectual property rights: the new enclosures? PB - Routledge CY - London/New York ID - May2000 ER - TY - BOOK AU - Drahos, P. PY - 2002 DA - 2002// TI - Information feudalism: who owns the knowledge economy? PB - The New Press CY - New York ID - Drahos2002 ER - TY - JOUR AU - Shaffer, E. R. AU - Brenner, J. E. PY - 2009 DA - 2009// TI - A trade agreement's impact on access to generic drugs JO - Health Aff VL - 28 UR - https://doi.org/10.1377/hlthaff.28.5.w957 DO - 10.1377/hlthaff.28.5.w957 ID - Shaffer2009 ER - TY - JOUR AU - Abbott, R. B. AU - Bader, R. AU - Bajjali, L. AU - ElSamen, T. A. AU - Obeidat, T. AU - Sboul, H. PY - 2012 DA - 2012// TI - The price of medicines in Jordan: the cost of trade-based intellectual property JO - J Generic Med VL - 9 UR - https://doi.org/10.1177/1741134312447499 DO - 10.1177/1741134312447499 ID - Abbott2012 ER - TY - BOOK PY - 2007 DA - 2007// TI - All costs, no benefits: how TRIPS-plus intellectual property rules in the US-Jordan FTA affect access to medicines ID - ref9 ER - TY - BOOK AU - Bollyky, T. PY - 2016 DA - 2016// TI - The TPP and drug prices: Why U.S. trade deals haven’t exported U.S. Drug Prices. Foreign Affairs ID - Bollyky2016 ER - TY - STD TI - Shadlen KC, Sampat BN, Kapczynski A. Patents, trade, and medicines: past, present, and future. Rev Int Polit Econ. 2019. https://doi.org/10.1080/09692290.2019.1624295. ID - ref11 ER - TY - BOOK PY - 2016 DA - 2016// TI - Text of the Trans-Pacific Partnership ID - ref12 ER - TY - STD TI - Office of the United States Trade Representative. Agreement between the United States of America, the United Mexican States, and Canada. https://ustr.gov/trade-agreements/free-trade-agreements/united-states-mexico-canada-agreement/agreement-between. Accessed 14 Dec 2018. UR - https://ustr.gov/trade-agreements/free-trade-agreements/united-states-mexico-canada-agreement/agreement-between ID - ref13 ER - TY - STD TI - Lexchin JR, Gleeson D. The Trans Pacific Partnership Agreement and pharmaceutical regulation in Canada and Australia. Int J Health Serv. 2016;46(4):597–613. ID - ref14 ER - TY - STD TI - United Nations. Sustainable development goals n.d. https://sustainabledevelopment.un.org/sdgs. Accessed 21 Sept 2018. UR - https://sustainabledevelopment.un.org/sdgs ID - ref15 ER - TY - STD TI - Gleeson D, Forman L. Implications of Trade and Investment Agreements for Access to Affordable Medicines and the Right to Health, Canadian Yearbook of Human Rights, Vol. II (2016-2018), HRREC-University of Ottawa. p. 148-56. In press ID - ref16 ER - TY - BOOK PY - 2003 DA - 2003// TI - How to Develop and Implement a National Drug Policy – WHO Policy Perspectives on Medicines, No. 006 ID - ref17 ER - TY - BOOK PY - 2011 DA - 2011// TI - Local Production for Access to Medical Products: Developing a Framework to Improve Public Health ID - ref18 ER - TY - STD TI - New Zealand Ministry of Foreign Affairs and Trade. Comprehensive and Progressive Agreement for Trans-Pacific Partnership text. https://www.mfat.govt.nz/en/trade/free-trade-agreements/free-trade-agreements-concluded-but-not-in-force/cptpp/comprehensive-and-progressive-agreement-for-trans-pacific-partnership-text/. Accessed 14 Dec 2018. UR - https://www.mfat.govt.nz/en/trade/free-trade-agreements/free-trade-agreements-concluded-but-not-in-force/cptpp/comprehensive-and-progressive-agreement-for-trans-pacific-partnership-text/ ID - ref19 ER - TY - STD TI - Government of Canada. Text of the Comprehensive Economic and Trade Agreement. https://international.gc.ca/trade-commerce/trade-agreements-accords-commerciaux/agr-acc/ceta-aecg/text-texte/toc-tdm.aspx?lang=eng. Accessed 14 Dec 2018. UR - https://international.gc.ca/trade-commerce/trade-agreements-accords-commerciaux/agr-acc/ceta-aecg/text-texte/toc-tdm.aspx?lang=eng ID - ref20 ER - TY - BOOK PY - 2013 DA - 2013// TI - The Global Use of Medicines: Outlook through 2017. IMS Health ID - ref21 ER - TY - JOUR AU - Lyman, G. H. AU - Zon, R. AU - Harvey, R. D. AU - Schilsky, R. L. PY - 2018 DA - 2018// TI - Rationale, opportunities, and reality of biosimilar medications JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMhle1800125 DO - 10.1056/NEJMhle1800125 ID - Lyman2018 ER - TY - STD TI - Gleeson D, Lexchin J, Lopert R, Kilic B. The Trans Pacific Partnership Agreement, intellectual property and medicines: differential outcomes for developed and developing countries. Glob Soc Policy. 2018;18(1):7–27. ID - ref23 ER - TY - STD TI - Pusceddu P. Assessing access to medicines in preferential trade agreements: from the Trans-Pacific Partnership to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership. In: IIC – International Review of Intellectual Property and Competition Law; 2018. ID - ref24 ER - TY - BOOK AU - Kilic, B. PY - 2018 DA - 2018// TI - NAFTA 2.0: U.S.-Mexico-Canada Agreement Chapter 20: Pharmaceutical Related Patent Provisions PB - Public Citizen CY - Washington D.C. ID - Kilic2018 ER - TY - STD TI - Lexchin J. Increase in drug spending in Canada due to extension of data protection for biologics: a descriptive study. Health Policy. 2019;14(3):10–8. ID - ref26 ER - TY - BOOK PY - 2018 DA - 2018// TI - Potential Savings from Biosimilars in Canada [Internet]. Patented Medicine Prices Review Board ID - ref27 ER - TY - BOOK AU - Lexchin, J. R. AU - Gagnon, M. -. A. PY - 2014 DA - 2014// TI - CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs. Globalization and Health UR - https://doi.org/10.1186/1744-8603-10-30 DO - 10.1186/1744-8603-10-30 ID - Lexchin2014 ER - TY - STD TI - Malpani R. All costs, no benefits: how the US-Jordan Free Trade Agreement affects access to medicines. J Generic Med. 2009;6(3):206–17. ID - ref29 ER - TY - JOUR AU - Jung, Y. AU - Kwon, S. PY - 2015 DA - 2015// TI - The effects of intellectual property rights on access to medicines and catastrophic expenditure JO - Int J Health Serv VL - 45 UR - https://doi.org/10.1177/0020731415584560 DO - 10.1177/0020731415584560 ID - Jung2015 ER - TY - JOUR AU - Jung, Y. AU - Kwon, S. PY - 2018 DA - 2018// TI - How does stronger protection of intellectual property rights affect national pharmaceutical expenditure? An analysis of OECD countries JO - Int J Health Serv VL - 48 UR - https://doi.org/10.1177/0020731418786095 DO - 10.1177/0020731418786095 ID - Jung2018 ER - TY - STD TI - Park W. Intellectual property rights and international innovation. In: Mascus K (ed). Frontiers of economics and globalization. Elsevier Science. 2007;1:289–327. ID - ref32 ER - TY - STD TI - Tienhaara K. The expropriation of environmental governance: protecting foreign investors at the expense of public policy. Cambridge/New York: Cambridge University press; 2009. ID - ref33 ER - TY - STD TI - Phillip Morris Asia Limited v. Commonwealth of Australia. UNCITRAL PCA Case No. 2012–12. https://www.italaw.com/cases/851. Accessed 29 Jan 2019. UR - https://www.italaw.com/cases/851 ID - ref34 ER - TY - STD TI - Johnson L, Sachs L. The TPP's investment chapter: entrenching, rather than reforming, a flawed system. CCSI policy paper. New York: Columbia Center on Sustainable Investment; 2015. ID - ref35 ER - TY - STD TI - Australian Government Department of Foreign Affairs and Trade. Chapter 8: Investment. Peru-Australia Free Trade Agreement. https://dfat.gov.au/trade/agreements/not-yet-in-force/pafta/full-text/Pages/chapter-8-investment.aspx. Accessed 19 May 2019. UR - https://dfat.gov.au/trade/agreements/not-yet-in-force/pafta/full-text/Pages/chapter-8-investment.aspx ID - ref36 ER - TY - BOOK AU - Hepburn, J. PY - 2019 DA - 2019// TI - Final costs details are released in Philip Morris v. Australia following request by IAReporter. Investment Arbitration Reporter ID - Hepburn2019 ER - TY - CHAP PY - 2018 DA - 2018// TI - Investor-State Dispute Settlement: Review of Developments in 2017 BT - IIA issues note: international investment agreements PB - UNCTAD CY - Geneva ID - ref38 ER - TY - STD TI - Labonte R, Schram A, Ruckert A. The Trans Pacific Partnership: is it everything we feared for health? Int J Health Policy Manag. 2016;5(8):487–96. ID - ref39 ER - TY - JOUR AU - Yu, P. K. PY - 2017 DA - 2017// TI - The investment-related aspects of intellectual property rights JO - Am UL Rev VL - 66 ID - Yu2017 ER - TY - STD TI - Eli Lilly and Company v. The Government of Canada, UNCITRAL, ICSID Case No. UNCT/14/2 n.d. https://www.italaw.com/cases/1625. Accessed 29 Jan 2019. UR - https://www.italaw.com/cases/1625 ID - ref41 ER - TY - JOUR AU - Baker, B. K. AU - Geddes, K. PY - 2017 DA - 2017// TI - The incredible shrinking victory: Eli Lilly v. Canada, success, judicial reversal, and continuing threats from pharmaceutical ISDS JO - Loyola University Chicago Law Journal VL - 49 ID - Baker2017 ER - TY - STD TI - New Zealand Ministry of Foreign Affairs and Trade. Trans-Pacific Partnership: pharmaceutical and medical device purchasing (reimbursement) fact sheet. Wellington: MFAT; 2015. ID - ref43 ER - TY - JOUR AU - Gleeson, D. AU - Menkes, D. M. PY - 2018 DA - 2018// TI - Trade agreements and direct-to-consumer advertising of pharmaceuticals JO - Int J Health Policy Manag VL - 7 UR - https://doi.org/10.15171/ijhpm.2017.124 DO - 10.15171/ijhpm.2017.124 ID - Gleeson2018 ER - TY - JOUR AU - Gilbody, S. AU - Wilson, P. AU - Watt, I. PY - 2005 DA - 2005// TI - Benefits and harms of direct to consumer advertising: a systematic review JO - Qual Saf Health Care VL - 14 UR - https://doi.org/10.1136/qshc.2004.012781 DO - 10.1136/qshc.2004.012781 ID - Gilbody2005 ER - TY - JOUR AU - Lexchin, J. AU - Mintzes, B. PY - 2002 DA - 2002// TI - Direct-to-consumer advertising of prescription drugs: the evidence says no JO - J Public Policy Mark VL - 21 UR - https://doi.org/10.1509/jppm.21.2.194.17595 DO - 10.1509/jppm.21.2.194.17595 ID - Lexchin2002 ER - TY - STD TI - Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med. 2010;7(10):e1000352. ID - ref47 ER - TY - STD TI - Lexchin J. Harmony in drug regulation, but who's calling the tune? An examination of regulatory harmonization in Health Canada. Int J Health Serv. 2012;42(1):119–36. ID - ref48 ER - TY - BOOK AU - Berman, A. PY - 2012 DA - 2012// TI - The distributional effects of transnational pharmaceutical regulation. CTEI working paper CTEI-2012-01 PB - The Graduate Institute CY - Geneva ID - Berman2012 ER - TY - JOUR AU - Lexchin, J. PY - 2012 DA - 2012// TI - New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? JO - Arch Intern Med VL - 172 UR - https://doi.org/10.1001/archinternmed.2012.4444 DO - 10.1001/archinternmed.2012.4444 ID - Lexchin2012 ER - TY - BOOK PY - 2018 DA - 2018// TI - Tariff Schedule of Viet Nam. New Zealand Ministry of Foreign Affairs and Trade ID - ref51 ER - TY - BOOK PY - 2018 DA - 2018// TI - Tariff Schedule of Mexico: United States Trade Representative ID - ref52 ER - TY - BOOK AU - Banik, N. AU - Stevens, P. PY - 2015 DA - 2015// TI - Pharmaceutical tariffs, trade flows and emerging economies PB - Geneva Network CY - Geneva ID - Banik2015 ER - TY - BOOK PY - 2012 DA - 2012// TI - Promoting Access to Medical Technologies and Innovation: Intersections between public health, intellectual property and trade PB - WTO, WIPO and WHO CY - Geneva ID - ref54 ER - TY - BOOK PY - 2011 DA - 2011// TI - Local production of pharmaceuticals and related technology transfer in developing countries: a series of case studies by the UNCTAD secretariat PB - UNCTAD CY - Geneva ID - ref55 ER - TY - BOOK PY - 1994 DA - 1994// TI - GATT 1994 Communication on Trade in Pharmaceutical Products ID - ref56 ER - TY - JOUR AU - Vu, H. T. PY - 2016 DA - 2016// TI - Assessing potential impacts of the EVFTA on Vietnam’s pharmaceutical imports from the EU: an application of SMART analysis JO - SpringerPlus. VL - 5 UR - https://doi.org/10.1186/s40064-016-3200-7 DO - 10.1186/s40064-016-3200-7 ID - Vu2016 ER - TY - JOUR AU - Gorski, J. PY - 2016 DA - 2016// TI - The impact of the TPP on opening government procurement to international competition in the Asia-Pacific region JO - Trade Law Dev VL - 8 ID - Gorski2016 ER - TY - STD TI - Australian Government Department of Foreign Affairs and Trade. Comprehensive and Progressive Agreement for Trans-Pacific Partnership (TPP-11) Outcomes Document: Health. Canberra: DFAT; 2018. https://dfat.gov.au/trade/agreements/not-yet-in-force/tpp-11/outcomes-documents/Pages/tpp-11-outcomes-health.aspx. Accessed 7 Dec 2018. UR - https://dfat.gov.au/trade/agreements/not-yet-in-force/tpp-11/outcomes-documents/Pages/tpp-11-outcomes-health.aspx ID - ref59 ER - TY - STD TI - Comprehensive and Progressive Agreement for Trans-Pacific Partnership. Annex 15-A: Schedule of Vietnam 2018. https://www.mfat.govt.nz/assets/Trans-Pacific-Partnership/Annexes/15-A.-Viet-Nam-Government-Procurement-Annex.pdf. Accessed 29 Jan 2019. UR - https://www.mfat.govt.nz/assets/Trans-Pacific-Partnership/Annexes/15-A.-Viet-Nam-Government-Procurement-Annex.pdf ID - ref60 ER - TY - JOUR AU - Dranitsaris, G. AU - Jacobs, I. AU - Kirchhoff, C. AU - Popovian, R. AU - Shane, L. G. PY - 2017 DA - 2017// TI - Drug tendering: drug supply and shortage implications for the uptake of biosimilars JO - ClinicoEcon Outcomes Res VL - 9 UR - https://doi.org/10.2147/CEOR.S140063 DO - 10.2147/CEOR.S140063 ID - Dranitsaris2017 ER - TY - STD TI - Sylvestre Fleury J, Marcoux J-M. The US shaping of state-owned Enterprise disciplines in the Trans-Pacific Partnership. J Int Econ Law. 2016;19(2):445–65. ID - ref62 ER - TY - STD TI - Angelino A, Khanh TD, An Ha N, Pham T. Pharmaceutical industry in Vietnam: Sluggish sector in a growing market. Int J Environ Res Public Health. 2017;14(9). https://doi.org/10.3390/ijerph14090976. ID - ref63 ER - TY - STD TI - Lin C-F, Liu H-W. Regulatory rationalisation clauses in FTAs: a complete survey of the US, EU and China. Melbourne J Int Law. 2018;19:1-29. ID - ref64 ER - TY - JOUR AU - Son, K. -. B. AU - Lee, T. -. J. PY - 2018 DA - 2018// TI - The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: implications for domestic legislations in low- and middle-income countries JO - Global Public Health VL - 13 UR - https://doi.org/10.1080/17441692.2017.1334807 DO - 10.1080/17441692.2017.1334807 ID - Son2018 ER - TY - STD TI - Walls HL, Smith RD, Drahos P. Improving regulatory capacity to manage risks associated with trade agreements. Global Health. 2015;11(14). https://doi.org/10.1186/s12992-015-0099-7. ID - ref66 ER -